Member Info for 60601971

Merry Xmas All

Bring on 2025

Ananda Pharma that should of read

Https://www.anandapharma.co.uk/

Sort it out ...........

Https://www.linkedin.com/posts/melissa-sturgess_good-piece-today-dr-nic-giummarra-either-activity-7272500252450988032-itXR?utm_source=share&utm_medium=member_android

Https://www.femtechworld.co.uk/features/new-research-points-to-potential-of-cannabinoids-in-gynaecological-conditions/

Https://www.linkedin.com/posts/charles-morgan-83a62513_come-and-have-a-look-at-what-we-are-doing-activity-7272591787536404480-MJJf?utm_source=share&utm_medium=member_android

As that has firmed up the foundations yet again!

As it's a premium to the last money round and probably around mid price when instigated!

As would of taken a little time, also we don't need the cash so could well of been an approach to want in which would be a very strong positive in my eyes

It looks that way with the numbers

And realise just how the natural bio marker that occurs makes administering mrx and its reversion of the disease very very notable! This is huge and given the numbers attached to this disease label this as potentially much bigger than epidolex

And very swiftly after the first study which is very good to see and again with very positive results

They wanted the near term potential!

We are building 3 x near term potentials so far!

Why did Jazz buy GW?

"The addition of GW further diversifies our commerical portfolio and innovative pipeline with therapies that are complementary to our existing business, including Epidiolex, a high-growth commercial product with near-term blockbuster potential.5 May 2021

Revenue in 2021 (TTM): £0.42 Billion

According to GW Pharmaceuticals 's latest financial reports the company's current revenue is £0.43 Billion. In 2020 the company made a revenue of £0.41 Billion an increase over the revenue in the year 2019 that were of £0.24 Billion.

0.42 billion

I prefer the Jazz paid 7+ Billion for GW story for epidolex especially when we are on the exact pathway with its epilepsy trial and with endo and neuropathic pain on top too! Could we be on a triple version of the Same story!

Especially with the calibre of sectorial heavy weights that are working with us and the recent GW Pharma quote now attached to Mellissa's profile in numerous locations of high presence on a very proffesional level, and given Charles outstanding past performance to deliver with huge valuations and successful exits within the biggest global markets!

Big vibes out of Vegas with Heidi representing us......watch this space!!!!

Here comes the looney from cookoo land! Lol

I was getting worried about you well I wasn't really as your too far gone...

Absolutely right we traded at triple the current price a few years back at a very early stage, so an approach or collab or successfull trial will blow the doors clean off

Get that big buy order through as it's clogging the system and people are waiting to top up!

Time to put an Endo to this undervalue!